How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/philadelphia-chromosome-positive-chronic-myelocytic-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Philadelphia Chromosome Positive Chronic Myelocytic Leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Philadelphia Chromosome Positive Chronic Myelocytic Leukemia (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Philadelphia Chromosome Positive Chronic Myelocytic Leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tasigna	NILOTINIB	Cipla	Kinase Inhibitor [EPC]	Bcr/Abl fusion protein	2007-01-01
Sprycel	dasatinib	Handa Therap	dasatinib	Ephrin type-B receptor 6	2006-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Busulfex	busulfan	Waylis	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
Tasigna	Tasigna	XSpray Microparticles		Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta
busulfex	busulfex	Dana-Farber Cancer Institute		Matrix metalloproteinase-9
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X
Busilvex	Busilvex	medac GmbH		Matrix metalloproteinase-9
Busulphan	Busulphan	University of Birmingham		Matrix metalloproteinase-9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Cipla · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Dana-Farber Cancer Institute · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Handa Therap · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
M.D. Anderson Cancer Center · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Novartis · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
University of Birmingham · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Waylis · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
XSpray Microparticles · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
medac GmbH · 1 drug in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Philadelphia Chromosome Positive Chronic Myelocytic Leukemia:

Cite this brief

Drug Landscape (2026). Philadelphia Chromosome Positive Chronic Myelocytic Leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/philadelphia-chromosome-positive-chronic-myelocytic-leukemia. Accessed 2026-06-10.

Philadelphia Chromosome Positive Chronic Myelocytic Leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing